Fig. 1: The targeted immunotherapeutic approaches for multiple myeloma.
From: Targeted immunotherapy: harnessing the immune system to battle multiple myeloma
CAR chimeric antigen receptor, PD-L1 programmed death-ligand 1, PD-1 programmed cell death protein 1, TCR T cell receptor, MHC major histocompatibility complex, NK cell natural killer cell.
